使用生物制剂治疗溃疡性结肠炎的思考

王化虹

doi:10.3969/j.issn.1671-038X.2023.04.04

使用生物制剂治疗溃疡性结肠炎的思考

王化虹^1, ,

- 北京大学第一医院消化内科(北京，100034)

详细信息

作者简介:
王化虹，北京大学第一医院消化内科主任医师，博导，国家消化重点专科学科带头人，第三届国之名医。现任中华医学会消化病学分会炎症性肠病学组委员和胃肠动力协作组副组长，中华医学会消化病学分会炎症性肠病诊疗质控评估指导中心委员会委员，中国医师协会循证医学委员会常委和临床营养专业委员会组长，北京医学会肠内外营养专业委员会常委，中华医学会北京微生态和Hp学会副主任委员，北京医师协会消化委员会副主委，北京医学奖励基金会微生态委员会副主委和炎症性肠病委员会常委，中国研究型医院学会中西医整合脾胃消化专委会副主委，中国医药教育协会炎症性肠病专业委员会副主委等

通讯作者: 王化虹，E-mail：wwwanghuahong@163.com

中图分类号: R574.62

收稿日期: 2023-02-08

刊出日期: 2023-04-15

Thoughts on the use of biological agents for treating ulcerative colitis

WANG Huahong^1, ,

- Department of Gastroenterology, the First Hospital of Peking University, Beijing, 100034, China

More Information

Corresponding author: WANG Huahong, E-mail: wwwanghuahong@163.com

Received Date: 08 February 2023

Publish Date: 15 April 2023

摘要

摘要: 近些年来，随着炎症性肠病在我国的发病率不断上升，特别是溃疡性结肠炎的发病患者越来越多，如何在溃疡性结肠炎患者的治疗中正确有效地使用生物制剂，给我们提出了很多问题，值得我们思考。
- 炎症性肠病 /
- 溃疡性结肠炎 /
- 生物制剂
Abstract: In recent years, with the increasing incidence of inflammatory bowel disease in China, especially ulcerative colitis, how to use biological agents correctly and effectively in patients with ulcerative colitis has raised many questions for us, which is worth thinking about.
- inflammatory bowel disease /
- ulcerative colitis /
- biological agents

HTML全文

参考文献(18)

[1]	中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中华消化杂志, 2018, 38(5): 292-311. doi: 10.3760/cma.j.issn.0254-1432.2018.05.002
[2]	中国炎症性肠病诊疗质控评估中心, 中华医学会消化病学分会炎症性肠病学组. 生物制剂治疗炎症性肠病专家建议意见[J]. 中华消化杂志, 2021, 41(6): 366-378. doi: 10.3760/cma.j.cn311367-20210304-00136
[3]	文士域. 溃疡性结肠炎23例之分析与探讨[J]. 人民军医, 1956, 7(8): 52. https://www.cnki.com.cn/Article/CJFDTOTAL-RMJZ195608022.htm
[4]	Singh S, Allegretti JR, Siddique SM, et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis[J]. Gastroenterology, 2020, 158(5): 1465-1496. e17. doi: 10.1053/j.gastro.2020.01.007
[5]	Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis[J]. Gut, 2010, 59(1): 49-54. doi: 10.1136/gut.2009.183095
[6]	Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis[J]. Gastroenterology, 2014, 147(6): 1296-1307. e5. doi: 10.1053/j.gastro.2014.08.035
[7]	Puri AS, Desai D, Sood A, et al. Infliximab-induced tuberculosis in patients with UC: Experience from India-a country with high prevalence of tuberculosis[J]. J Gastroenterol Hepatol, 2017, 32(6): 1191-1194. doi: 10.1111/jgh.13669
[8]	Sandborn WJ, Van Assche G, Reinisch R, et al. Adalimumab induces and maintains remission in patients with miderate-to-severe ulcerative colitis[J]. Gastroenterology, 2012, 142(2): 257-265. doi: 10.1053/j.gastro.2011.10.032
[9]	Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial[J]. Gut, 2011, 60(6): 780-787. doi: 10.1136/gut.2010.221127
[10]	Ozcaglar C, Shabber A, Vandenberg SL, et al. Epidemiological models of Myobacterium tuberculosis complex infections[J]. Mathematic Biosciences, 2012, 236(2): 77-96. doi: 10.1016/j.mbs.2012.02.003
[11]	Chaparro M, Garre A, Iborra M, et al. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry[J]. J Crohns Colitis, 2021, 15(11): 1846-1851. doi: 10.1093/ecco-jcc/jjab070
[12]	Singh S, Murad MH, Fumery M, et al. First-and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis[J]. Clin Gastroenterol Hepatol, 2020, 18(10): 2179-2191. e6. doi: 10.1016/j.cgh.2020.01.008
[13]	Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis[J]. Gastroenterology, 2020, 158(3): 562-572. e12. doi: 10.1053/j.gastro.2019.08.027
[14]	Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2020, 52(8): 1353-1365. doi: 10.1111/apt.16060
[15]	Lopez-Sanroman A, Esplugues JV, Domenech E. Pharmacology and safety of tofacitinib in ulcerative colitis[J]. Gastroenterol Hepatol, 2021, 44(1): 39-48. doi: 10.1016/j.gastrohep.2020.04.012
[16]	Bokemeyer B, Picker N, Wilke T, et al. Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data[J]. Inflamm Bowel Dis, 2022, 28(11): 1647-1657. doi: 10.1093/ibd/izab330
[17]	Shmais M, Regueiro M, Hashash JG. Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?[J]. Inflamm Intest Dis, 2022, 7(1): 50-58. doi: 10.1159/000518755
[18]	Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases[J]. Drugs, 2020, 80(2): 99-113. doi: 10.1007/s40265-020-01256-5